Image

Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI

Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI

Recruiting
18-80 years
All
Phase N/A

Powered by AI

Overview

This is an multicenter, randomized, controlled, parallel group study. ST-Segment Elevation Myocardial Infarction (STEMI) patients with high thrombus burden(HTB) will be allocated to one of the following: intrathrombus thrombolysis or manual aspiration thrombectomy during primary percutaneous coronary intervention(PPCI).

Description

The hypothesis for ATTRACTIVE trial is that the intrathrombus thrombolysis with microcatheter or pierced balloon compared to manual aspiration thrombectomy will reduce the incidence of major adverse cardiovascular events(MACEs), including cardiovascular death, recurrent myocardial infarction, cardiogenic shock, or heart failure rehospitalization, stent thrombosis and target-vessel revascularization at 1 year in STEMI patients with HTB undergoing PPCI.

Eligibility

Inclusion Criteria:

  1. Patients presenting with:
    • Symptoms of myocardial ischemia lasting for ≥ 30 minutes AND
    • Definite ECG changes indicating STEMI: ST elevation of greater than 0.1 mV in two contiguous limb leads or 0.2 mV in two contiguous precordial leads
  2. Referred for PPCI
  3. Within 12 hours of symptom onset, or 12-24 hours but still suffered from persistent symptom, hemodynamic instability or fatal arrhythmia
  4. High thrombus burden:
    • TIMI thrombus grade 3 or 4 after emergency coronary angiography
    • Or TIMI thrombus grade ≥3 after guidewire crossing or 1.5mm-diameter predilating the culprit lesion if emergency coronary angiography shows TIMI thrombus grade 5
  5. Informed consent

Exclusion Criteria:

  1. Rescue PCI after systemic thrombolysis
  2. Previous CABG history
  3. Life expectancy<1 year
  4. Active bleeding in past 6 months, hemorrhagic disorders and prone to bleeding
  5. Serious hepatic or kidney dysfunction
  6. Pregnancy and lactation
  7. Uncontrolled hypertension (>180/100mmHg)
  8. Previous hemorrhagic stroke or ischemic stroke in past 3 months
  9. Cardiogenic shock or cardio-pulmonary resuscitation
  10. Informed consent cannot be obtained or follow-up cannot be completed

Study details
    Acute Coronary Syndrome
    ST Elevation Myocardial Infarction
    Percutaneous Coronary Intervention

NCT05554588

China-Japan Friendship Hospital

25 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.